Nephrotect

Valine, Acetylcysteine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine, the active ingredients in Nephrotect, are a blend of amino acids presented as an intravenous solution for parenteral use. It is intended to support renal function and metabolic balance in patients requiring amino‑acid supplementation.

GNH USA supplies Nephrotect as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for importers and ensures timely delivery across all regions.

Nephroprotect is an intravenous amino‑acid formulation that may be employed to support renal health and metabolic needs in various clinical contexts.

Adjunctive therapy in renal replacement therapy: provides essential amino acids to maintain plasma protein synthesis during dialysis. Peri‑operative renal protection: supplementation may help mitigate amino‑acid depletion associated with major surgery and improve postoperative recovery. Chronic kidney disease nutritional support: assists in preserving nitrogen balance when oral intake is insufficient or restricted.

Nephroprotect, like other intravenous amino‑acid solutions, may be associated with a range of adverse reactions.

Common Side Effects: - Infusion site erythema: localized redness or mild swelling at the injection site. - Transient nausea: brief feeling of nausea during or shortly after infusion. - Mild hypotension: temporary drop in blood pressure, often asymptomatic. - Headache: mild to moderate headache occurring during treatment.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical intervention. - Severe hyperammonemia: elevated blood ammonia levels leading to neurological symptoms. - Metabolic acidosis: significant acid‑base disturbance requiring correction. - Renal tubular injury: rare direct toxicity to renal tubules manifesting as impaired function.

Prior to administering Nephroprotect, clinicians should observe several safety precautions to minimize risk.

- Assess renal function: evaluate baseline creatinine and electrolyte status before infusion. - Monitor infusion rate: administer slowly to reduce risk of hypotension and related events. - Check for hypersensitivity: discontinue immediately if signs of allergy such as rash or bronchospasm appear. - Avoid in severe hepatic impairment: risk of ammonia accumulation may be heightened. - Review concomitant nephrotoxic drugs: adjust therapy when used with agents like aminoglycosides or contrast media. - Store at ambient temperature: keep in original container, protect from light and moisture.

Nephroprotect may interact with certain medications; awareness of these interactions assists in safe co‑administration.

Major Interactions (Avoid): - Concurrent high‑dose N‑acetylcysteine: may cause excessive sulfhydryl load and renal stress. - Co‑administration with aminoglycoside antibiotics: increased risk of nephrotoxicity. - Combination with valproate or other ammonia‑raising agents: potential for severe hyperammonemia.

Moderate Interactions (Monitor Closely): - Use with intravenous lipid emulsions: may alter amino‑acid distribution and plasma levels. - Concomitant diuretics: monitor electrolytes and fluid balance closely. - Vitamin B6 supplementation: may affect metabolism of certain amino acids, requiring observation.